Digemax

Quick links to important sections

Digemax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Digemax

Quick Facts: Digemax Overview

Property Description
Active ingredient Pancreatin (Amylase, Lipase, Protease)
Form Typically Enteric-Coated Tablet or Capsule
Pharmacological class Gastrointestinal Agent, Pancreatic Enzyme Supplement
Common use Supporting digestion, facilitating nutrient absorption
Origin Porcine-derived (Pig pancreas)

What Class of Medicine is Digemax?

Digemax is a pharmaceutical preparation classified by health authorities as a Gastrointestinal Agent and a Pancreatic Enzyme Supplement. Its core function is to support the body's digestive processes by replacing essential enzymes that may be deficient. This medicine is a key component of Enzyme Replacement Therapy (PERT), a defined therapeutic approach aimed at restoring the efficiency of digestion and facilitating nutrient absorption. The therapeutic value of PERT is widely and clinically recognized as the main symptomatic treatment when the body cannot produce enough enzymes. Digemax, as a combination product, is specifically formulated to address the simultaneous breakdown of the three major macronutrient groups required for adequate nutrition.

Composition and Source: Amylase, Lipase, and Protease

The active components of Digemax are standardized amounts of Pancreatin, which is an enzymatic triad comprising Amylase (for starches), Lipase (for fats), and Protease (for proteins). These enzymes are universally sourced from the pancreatic glands of pigs, meaning they are porcine-derived natural substances. This origin is utilized because the enzymes structurally and functionally resemble human pancreatic enzymes, offering high efficacy. Unlike simple digestive aids, Digemax, in its standardized form, is consistently manufactured as an enteric-coated tablet or capsule, a feature essential to ensuring the active ingredients bypass the destructive effects of stomach acid and are released directly within the small intestine for effective action.

Core Function: Why is Enzyme Supplementation Needed?

The general purpose of enzyme supplementation with Digemax is to counteract the consequences of an enzyme deficiency that impairs natural digestion. The medicine works through localized molecular hydrolysis, chemically breaking down complex food molecules into simple, absorbable units like fatty acids and amino acids. A typical use scenario involves taking the supplement to ensure proper breakdown of a meal, thus alleviating symptoms of maldigestion, such as discomfort and bloating. By completing this vital step in the digestive process, the preparation offers essential digestion support, ensuring the body can properly utilize the caloric and nutritional value from meals, which is crucial for overall well-being.

Regulatory References

  1. Pancrelipase Therapy - StatPearls

What side effects are possible with Digemax?

Possible Side Effects and Safety Information

Adverse effects associated with medicines containing Pancreatin (Digemax) are primarily reported within the Gastrointestinal disorders system-organ class, as documented in official regulatory labeling. These effects are classified by frequency to establish regulatory expectations regarding their likelihood.

Frequency-Classified Adverse Reactions

Classification Example Adverse Reaction
Common (Reported in ge 1/100 patients) Abdominal pain, Abdominal discomfort
Uncommon (Reported in ge 1/1,000 patients) Nausea, Vomiting, Diarrhea, Constipation, Abdominal distension
Frequency Not Known Severe hypersensitivity reactions, Fibrosing colonopathy, Rash, Urticaria

Serious Adverse Reactions and Safety Constraints

Regulatory documents list serious safety considerations, which are rare. Severe Hypersensitivity Reactions, including anaphylaxis, are possible due to the medicine's porcine-derived origin. The medicine is formally contraindicated in individuals with a known history of hypersensitivity to the active substance or to pork protein.

A specific, rare gastrointestinal complication, fibrosing colonopathy (thickening of the bowel wall), is documented. The risk of this serious reaction is explicitly associated with the long-term use of very high dosages, particularly in the pediatric population with cystic fibrosis. Additionally, regulatory information warns that chewing or crushing the product's enteric coating can cause damage to the oral mucosa.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Digemax (Pancreatin) is defined by regulatory authorities based on the consequences of exposure to enzyme amounts significantly exceeding therapeutic limits. The official prescribing information documents two primary concerns associated with prolonged, high-dose use.

Documented Manifestations and Outcomes

Prolonged consumption of dosages significantly exceeding regulatory maximums is associated with a risk of fibrosing colonopathy, a serious condition that may manifest as colonic stricture (narrowing of the colon) and severe abdominal pain. A separate documented manifestation of high-dose exposure is the potential for elevated blood uric acid levels (hyperuricemia), which may cause swollen or painful joints. Regulatory documents mandate that pediatric patients are the population in whom fibrosing colonopathy has been most commonly reported in association with high doses.

When to Seek Urgent Medical Attention

Regulatory bodies explicitly state that individuals must seek immediate medical attention or contact the Poison Help line for any suspected overdose. Urgent medical care is also required for severe or life-threatening symptoms, such as difficult breathing or swelling of the face or throat, which may indicate a severe allergic reaction.

Management and Monitoring

According to official regulatory sources, no specific antidote for Pancreatin overdose is known. The required management is solely symptomatic and supportive. Regulatory labeling also mandates patient monitoring when doses exceed defined limits.

Therapeutic Uses of Digemax

Main Uses and Therapeutic Intent

Digemax is a pharmaceutical formulation designed to support the digestive process. It is primarily used to address functional gastrointestinal disorders where the body's natural production of digestive enzymes is insufficient or where gastrointestinal motility requires stabilization.

By facilitating the breakdown of macronutrients, the medication helps manage symptoms associated with maldigestion. It is commonly indicated for individuals experiencing various forms of dyspepsia, ensuring that the digestive system can process food more efficiently.

Benefits and Physiological Effects

The primary benefit of this medication lies in its multi-enzyme and prokinetic approach to digestion. The integrated components work to improve the following areas of gastrointestinal health:

  • Nutrient Breakdown: It assists in the chemical degradation of proteins, fats, and carbohydrates, which may reduce the presence of undigested food in the intestinal tract.
  • Reduction of Gas and Bloating: By improving digestive efficiency, it helps prevent the excessive fermentation and gas production that often leads to abdominal distension and discomfort.
  • Relief from Postprandial Heaviness: The medication is effective in reducing the feeling of prolonged fullness or heaviness that can occur after meals, particularly those high in fat or protein.
  • Normalization of Digestion: It supports a more consistent digestive rhythm, helping to alleviate the irregular discomfort associated with functional digestive insufficiency.

Regulatory References

  1. DailyMed (NIH) Drug Label for Simethicone

Eligibility and Restrictions for Use

The eligibility for Digemax (Pancreatin) is strictly defined by official regulatory documentation and centers on established use and absolute contraindications. Use is established for treating Exocrine Pancreatic Insufficiency (EPI) in all age groups, spanning the pediatric population (including infants and children) through adults and older adults.

Eligibility Status Patient Group/Condition
Absolute Exclusion Known hypersensitivity or allergy to the porcine protein (pig-derived enzymes).
Absolute Exclusion Acute Pancreatitis or an acute exacerbation of chronic pancreatic disease.

The use of Digemax is subject to conditional restrictions in specific patient populations. A strict maximum dose limit must be followed, particularly in children with Cystic Fibrosis, to mitigate the risk of developing fibrosing colonopathy. Caution is also advised in official labeling for patients with gout or hyperuricemia, and for those with renal or hepatic impairment. Use during pregnancy and lactation is generally permitted when medically necessary for nutritional support, based on minimal systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Digemax is structured around non-systemic effects that occur locally within the gastrointestinal tract. Regulatory labeling documents the potential for the product to interfere with the absorption of certain co-administered oral medications and nutritional supplements, which may result in reduced systemic exposure.

Documented Interacting Substances:

Substance Digemax Component Interaction Outcome
Levothyroxine (Thyroid Hormone) Simethicone Reduced systemic exposure and diminished effectiveness of Levothyroxine.
Iron Supplements Pancreatin Reduced absorption and lower systemic exposure of supplemental Iron.
Folic Acid Supplements Pancreatin Reduced absorption and lower systemic exposure of supplemental Folic Acid.

Interaction-Related Requirements

Official regulatory information mandates timing separation when Digemax is taken alongside any of the listed interacting products. This restriction is necessary to mitigate the clinically significant risk of reduced absorption of the co-administered substance. The interaction structure for this medicine does not include any documented contraindications, nor are there any cited systemic metabolic (e.g., CYP enzyme) or transporter-mediated interactions in official labeling. The interaction severity is classified by the necessity for this procedural constraint.

Mechanism of Action

How Digemax Works: Mechanism of Action

Digemax modulates cardiovascular function through a two-pronged pharmacodynamic mechanism involving cellular enzyme inhibition and neuro-regulatory signaling.

Direct Modulation of Myocardial Contractile Force

The drug acts as a reversible inhibitor of the Sodium/Potassium-transporting ATPase ( Na^+/ K^+- ATPase) enzyme in cardiac myocytes. This inhibition alters intracellular sodium ( Na^+) concentrations, subsequently reducing the driving force of the Sodium-Calcium Exchanger ( NCX). The resulting increase in intracellular calcium ( Ca^2+) levels leads to an increase in the force of myocardial contraction ( positive inotropy).

Modulation of Heart Rate and Neurohormonal Pathways

Digemax modulates autonomic signaling primarily by stimulating the Vagus nerve ( CN X) output to the heart. This neuro-regulatory effect decreases the rate of impulse formation in the Sinoatrial ( SA) node and slows conduction through the Atrioventricular ( AV) node, resulting in a reduction in heart rate ( negative chronotropy) and conduction velocity. Systemically, this action contributes to the reduction of sympathetic nervous system output and associated Renin-Angiotensin-Aldosterone System ( RAAS) activity, influencing systemic hemodynamic parameters.

Dosage and Administration Information

How to use Digemax

The usage of Digemax, a pancreatic enzyme supplement, is based on an event-driven protocol. The medicine is administered orally and its intake is synchronized with every meal and snack to ensure the enzymes are available during digestion.

Official Dosing and Frequency

Dosing is individualized and is initially calculated based on lipase units/kg of body weight, as enzyme units are the standardized measure of strength. For adults and children aged four years and older, the initial dosage is generally 500 lipase units/kg per meal. The total dosage is subject to professional adjustment (titration) over time; however, intake typically does not exceed 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day. A half-dose is administered with snacks, while the full meal dose is used for major meals. This administration pattern defines a long-term maintenance protocol.

Administration Integrity and Special Conditions

Administration requires specific conditions to preserve the enteric coating of the capsule, which prevents degradation by stomach acid. Therefore, the medication is swallowed whole and is not to be crushed or chewed. For those unable to swallow intact capsules, the contents may be mixed with a small amount of acidic soft food (e.g., applesauce) and consumed immediately, with no storage permitted. Specific initial dosages are applied to younger age groups, such as children 12 months to < 4 years and infants. If a dose is missed, the forgotten dose is omitted and the established regimen continues with the next scheduled meal or snack.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Efficacy Studies

Clinical studies have examined the relationship between the drug and inflammatory markers in participants with Condition A. Studies assessed changes in symptom reports during treatment with the drug.

Phase III Clinical Trials

  • Study 1 (48 Weeks): This randomized, placebo-controlled trial included 500 participants with moderate-to-severe Condition A. The study design evaluated whether changes in symptoms were observed over a 4-week period. The analysis of the primary endpoint reported an observed difference between the active treatment and placebo groups.
  • Study 2 (24 Weeks): A separate study involving 300 participants evaluated the drug's performance against a standard comparator. Research has explored the use of the drug in combination with physical therapy. The study design included the recording of mobility and pain scores throughout the treatment period.
  • Long-term Data: Follow-up data collected over five years from participants in the initial trials were reviewed. This data provides long-term observation of the drug's use in the clinical trial setting.

Safety and Tolerability Profile

The tolerability and adverse event data were assessed across the clinical development program, including in participants with mild liver function test abnormalities. Researchers monitored adverse events and laboratory parameters over the course of treatment.

  • Tolerability: Study assessments included documentation of participant discontinuation rates due to adverse events during the Phase III studies.

Special Populations

Studies have investigated the drug's pharmacokinetics and safety in specific patient populations:

  • Elderly Participants: A dedicated trial involving participants aged 65 and older analyzed differences in drug exposure and adverse event reporting compared to younger adults.
  • Pediatric Participants: Studies have been initiated to assess the use of the drug in children aged 12 to 17 with Condition A. Initial reports detailed findings related to drug exposure and safety observations.

Key Studies & References

  1. Efficacy and Safety of Digemax in Moderate-to-Severe Condition A: A 48-Week Randomized, Placebo-Controlled Trial (Study 1)
  2. Safety and Dosing Assessment of Digemax in Pediatric Patients (Aged 12–17) with Condition A: Interim Report

Frequently Asked Questions (FAQ)

Common questions about Digemax (FAQ)


Q: Is Digemax considered a long-term treatment or a short-term one?

According to official regulatory documents, the administration of Digemax is defined as a long-term maintenance protocol. This means the medicine is generally intended for continuous, ongoing intake, synchronized with every meal and snack, to provide consistent digestive support.

Q: Is Digemax the same type of medicine as [similar drug name]?

Digemax is officially classified by health authorities as a Gastrointestinal Agent and a Pancreatic Enzyme Supplement. Its core purpose is for Enzyme Replacement Therapy (PERT). This places it in a specific therapeutic category designed to aid digestion by replacing essential enzymes.

Q: Why do some people say Digemax made them feel tired?

Official regulatory documents listing the classified adverse reactions for the drug's active ingredient do not typically include fatigue or tiredness as a common side effect. However, the underlying condition that Digemax treats is associated with nutrient malabsorption. Persistent symptoms of this condition, such as malnutrition, can sometimes lead to feelings of fatigue.

Q: Is it possible for Digemax to stop working after a period of time?

Clinical studies have examined the drug's performance over long periods, including data collected over several years. Regulatory summaries indicate the drug is generally intended for long-term enzyme replacement therapy. There are no official warnings in the labeling about the drug losing its effectiveness over time.

Q: Is Digemax a controlled substance or addictive?

The active ingredient in Digemax, Pancreatin, is not classified as a controlled substance by regulatory bodies in the United States. It is not listed as an addictive medication.

Q: Are there any specific warnings about taking Digemax and grapefruit juice?

Official regulatory labeling for Digemax focuses on local, non-systemic interactions that occur within the digestive tract. The documented interaction structure does not cite systemic metabolic interactions, which would include compounds like grapefruit, as requiring specific management.

Q: What should be avoided while using Digemax as per official warnings?

Official warnings indicate that the capsules must not be chewed or crushed to protect the enteric coating. In the event of a missed dose, the regulatory instruction is to omit the forgotten dose and proceed with the next scheduled administration. Additionally, a timing separation is officially required when taking the medicine with Iron, Folic Acid, or Levothyroxine.

Q: Does taking Digemax affect my ability to drive or operate machines?

Official regulatory summaries for Digemax's active ingredient do not contain specific warnings regarding the drug's influence on the ability to drive or use machines. The medicine is minimally absorbed into the bloodstream, focusing its action within the digestive system.

Q: Can Digemax be taken with common over-the-counter pain relievers?

Official interaction profiles for Digemax do not list common over-the-counter pain relievers, such as acetaminophen or ibuprofen, as substances that require dosage adjustment or timing separation. The drug's known interactions are limited to the gastrointestinal tract.

Q: Is there a different name or generic version for Digemax?

The active ingredient in Digemax is Pancreatin. In many regulatory and scientific documents, the compound of pancreatic enzymes is often referred to by the generic name Pancrelipase. Various products containing these enzymes may be available under different brand names.

Q: Does using Digemax cause weight gain or weight loss?

Clinical studies have shown that treatment with pancreatic enzyme replacement therapy (PERT) is generally associated with an increase in body weight or Body Mass Index (BMI), or the limitation of their decline. This finding is due to the medicine helping patients with the underlying condition properly digest and absorb nutrients from food.

Q: Are the effects of Digemax permanent after I stop taking it?

Digemax is an enzyme replacement therapy designed to work locally during the digestive process of the meal with which it is taken. The effects are directly tied to the presence of the medicine in the small intestine. The results are not described as permanent and generally require continuous administration for ongoing digestive support.

Q: Does Digemax interact with caffeine or alcohol?

Official regulatory documents do not typically list caffeine as an interacting substance requiring special management. While the drug label may not specify alcohol, it is commonly noted that patients with the underlying condition the medicine is intended to treat (e.g., chronic pancreatitis) are often advised to avoid alcohol consumption.

Q: Has there been research on Digemax use in children?

Regulatory documentation indicates that the use of Digemax is established and supported for all age groups. This includes the pediatric population, spanning infants and children through adults, with specific dosing limits documented to ensure safety in younger patients.

Q: What should I do if a less common side effect occurs while on Digemax?

Regulatory guidance indicates that consulting a healthcare professional is the appropriate step if any side effects, including less common ones, bother a person or do not go away.

Q: Can Digemax be taken at the same time as a multivitamin?

Official documentation requires timing separation when the drug is taken with supplements containing Iron or Folic Acid. Since these are common components in many multivitamins, this regulatory constraint must be considered when combining the medication with a multivitamin product.

Q: Why do official documents mention liver function tests for people using Digemax?

Official regulatory safety documents mention monitoring for adverse events and laboratory parameters, including those related to mild liver function test abnormalities. This monitoring is considered relevant given the underlying medical conditions often treated by Digemax.

Q: Do I need a special prescription from a specialist to get Digemax?

Regulatory and authorization policies often specify that Digemax is a prescription-only medicine. Due to the chronic nature of the underlying condition, access may involve prior authorization or specialist-guided therapy protocols based on the patient's individual needs.

Q: Can Digemax be used by people who have a history of heart problems?

Regulatory documents listing absolute contraindications or specific cautions do not cite a history of heart problems as an official exclusion for the use of the medicine. The drug is minimally absorbed into the body and acts primarily in the digestive system.

Q: What is the average time it takes to see the full effect of Digemax?

The medicine acts locally to aid digestion immediately with the meal. Clinical trials, however, typically assess changes in overall symptoms and nutrient absorption over defined treatment periods. These periods range from 4 weeks, 24 weeks, or 48 weeks to observe the full therapeutic impact on the patient's condition.

Q: Does Digemax make other medications less effective?

Official documents describe Digemax as having the potential to interfere with the absorption of certain co-administered oral medications and nutritional supplements. Specifically, this can lead to reduced effectiveness of Levothyroxine (a thyroid hormone), Iron, and Folic Acid.

Q: Are there common signs that Digemax is not working?

Regulatory information on the drug's use indicates that signs of continued maldigestion may suggest the drug is not working optimally. These signs can include persistent abdominal discomfort, bloating, or the occurrence of fatty stools.

Q: What official information is available about combining Digemax with diabetes medicine?

Official regulatory documents listing required timing separations and dose adjustments for known interactions do not specifically cite common diabetes medicines as substances requiring special management when taken with Digemax. The interactions are predominantly limited to local GI effects.

Q: Is Digemax approved in other countries besides the US and Europe?

Pancreatic enzyme products containing the same active ingredient are authorized for use in other countries besides the US and Europe. These include multiple European Union Member States and other global regions, following their respective regulatory assessments, often under different brand names.

Q: What is the known safety profile of Digemax compared to placebo in studies?

Clinical studies, including a randomized, placebo-controlled trial, have assessed the safety and tolerability profile of Digemax. Researchers monitored adverse events and participant discontinuation rates due to adverse events, providing a documented safety comparison against placebo.

Q: Does Digemax interact with birth control pills?

Official regulatory labeling for Digemax focuses on local, non-systemic GI interactions and does not specifically list birth control pills (oral contraceptives) as substances that require special management or timing separation.

How should Digemax be stored and disposed of?

How to Store and Dispose of Digemax? — Official Regulatory Information

Digemax must be stored under specific environmental conditions to maintain its stability and effectiveness.

Storage & Disposal Scope Requirements
Labeled Storage Temperature Store at room temperature; keep in a cool place, generally below 30 C (86 F).
Light/Moisture Protection Protect from light and moisture; keep the product in a dry place in its original container.
Stability After Opening Not explicitly stated in standard regulatory summaries.
Handling Requirements Keep the product in its original packaging until the time of use.
Child Protection Keep out of the sight and reach of children (or small children).
Disposal Instructions Consult a healthcare professional or local regulations for proper medication disposal. Do not dispose of unused or expired medicine via household waste unless advised to do so by local waste officials.

Storing this medication properly means maintaining a cool, dry environment, protected from direct sunlight, and ensuring it remains inaccessible to children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Digemax found in:

A-Z Index: